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Abstract 
This study reviews the outcomes of the 225 Transcatheter Aortic Valve Replacement Procedures that were 
performed over the past three years at Lehigh Valley Health Network. It was performed as a retrospective chart 
review to evaluate the mortality and stroke rates for patient demographics such as age, gender, and various 
comorbidities. Patients performed better with decreasing comorbidities and a low percentage required pacemaker 
implantation after surgery. This study shows that TAVR procedures can be performed safely at a tertiary academic 
community hospital with excellent outcomes compared to the PARTNER trials and commercial roll-out studies.  
 
Introduction 
Severe Aortic Stenosis (AS) is the narrowing or obstruction of the aortic valve that results in fatigue, shortness of 
breath, and, in extreme cases, hospitalization or death.
1
 In the past, surgical aortic valve replacement (SAVR), which 
requires a sternotomy and cardiopulmonary bypass, was the only option for patients with this condition. During this 
procedure, the cardiothoracic surgeon opens the chest, removes the aortic valve and replaces it with a prosthetic 
valve.
2
 Many patients with aortic stenosis, however, are considered inoperable or high-risk due to age, frailty, and 
other comorbidities. These patients, often denied surgical aortic valve replacement (SAVR), are alternatively being 




Transcatheter aortic valve replacement (TAVR) is a transformative procedure that avoids the need for conventional 
open-heart aortic valve replacement in high-risk patients.
3
 These patients now have the option of TAVR, a less 
invasive procedure that uses a sheath to implant the prosthetic valve into the existing aortic valve. The catheter is fed 
into either the groin (transfemoral) or the chest (transapical) and then guided through the blood vessel into the aorta.
4
 
The transfemoral approach is more common, however, the transapical approach is performed if the patient has 
coronary artery disease.
2
 Although the procedure is considered less invasive, it has not yet been cleared for low-risk 
patients. In order to be considered high-risk, the patient must have several comorbities that prevent him or her for 
being a viable candidate for surgical aortic valve replacement.
4 
 
The Food and Drug Administration approved TAVR in 2011
5
 and shortly after on May 16, 2012, the team of 
cardiologists and cardiothoracic surgeons at Lehigh Valley Health Network (LVHN) started performing this 
innovative procedure.
6
 Three years later, 225 procedures have been performed with great success. The purpose of 
this analysis was to assess the outcomes of all the TAVR procedures conducted at LVHN, a tertiary academic 
community hospital, over the past three years. Mortality rates and stroke rates were evaluated based on certain 
patient demographics such as age, sex and relevant comorbidities. A study was also conducted to determine the rate 
of pacemaker implantation.   
 
Methodology 
A retrospective chart review was performed with approval of the Lehigh Valley Health Network Department of 
Surgery as a quality improvement (QI)/process improvement (PI) project with permission to report in the literature 
using the SQUIRE guidelines. The TAVR procedure was performed 225 times over the course of three years in 
patients with severe aortic stenosis. These patients were deemed inoperable, or high-risk, for surgical aortic valve 
replacement during the TAVR clinic and were therefore considered to be good candidates for the TAVR procedure. 
Age, gender, comorbidities, patient mortality, stroke, and pacemaker implantation were determined by reviewing the 
patient records. All patients were evaluated to determine the mortality and stroke rates. Only patients without 
pacemakers prior to surgery were evaluated to determine the rate of pacemaker implantation after surgery. The 
comparison data from the PARTNER Trials was taken from the study, “Clinical Outcomes at 1 Year Following 





A review of the first 3 years shows 225 TAVR procedures were performed, 134 Trans-Femoral (TF), 91 Trans-
Apical (TA). The patient population was 120 men and 105 women, age ranging from 50 to 99, 41 of whom were 
less than 75 years old, 96 were 75 to 84 years old, 81 were 85 to 94 years old, and 1 was greater than 95 years old.  
Overall in-hospital mortality was 4 (1.78%); 30-day mortality 7 (3.11%); 60-day mortality 8 (3.56%); 1-year 
mortality 27 (12%).  Complications included stroke 11 (4.89%), need for pacemaker 41 (21.81%). The 4 in-hospital 
deaths were due to stroke (1), liver failure (1), cardiac failure (1), and hemorrhage (1).  Regrettably, some of the 
patient demographics only contained a few individuals for LVHN in comparison to the many STS/AVT Registry 







Figure 1: A comparison of the LVHN and STS/ACC TVT Registry
4
 Mortality rates for the various patient 


























































































































































Figure 2: A comparison of the LVHN and STS/ACC TVT Registry
4
 Stroke rates for the various patient 




The purpose of this study was to assess the outcomes of all the TAVR procedures that were performed over the past 
three years. Out of 26 conditions, only 3 of LVHN’s mortality rates were higher than those of the STS/ACT registry 
and out of 23 conditions, 15 of LVHN’s stroke rates were higher than those of the STS/ACT registry. The low 
percentage of pacemaker implantation indicates that the patients often return to normal rhythm after surgery, which 
allows for an easier recovery. Pacemaker implantation requires an additional procedure that requires a longer stay 
for the patient and additional bills that are unfavorable for both the hospital and the patient. In general, patients 
performed better with lower age, higher left ventricular ejection fraction (LVEF%), zero to moderate COPD, lower 
creatinine levels, and no preoperative atrial fibrillation. The transfemoral approach has overall better outcomes. This 
is most likely because patients undergoing the transapical approach often have coronary artery disease. Patients with 
less comorbidities, and therefore lower STS Prom %, had overall better outcomes.  
 
Altogether, these results confirm that TAVR procedures can be performed safely at a tertiary academic community 
hospital with excellent outcomes compared to the PARTNER trials and commercial roll-out studies. Factors 
predicting success include an existing high volume of interventional cardiology and cardiac surgical program, 
documented quality outcomes, a hybrid operating room, and the ability for the interventional cardiologists and 
cardiac surgeons to work as a collaborative team. 
 
The limitation to this study includes the low number of patients (225) at LVHN in comparison to the high number of 
patients in the PARTNER trials (12,182). Some of the demographics were underrepresented (e.g. only 1 patient over 

















































































































receive the same brand of valve. While most of the patients received the Edwards SAPIEN valves, some patients 
received the Medtronic CoreValve. It is difficult to determine whether patients performed superior with one valve or 
the other because so few patients received the Medtronic CoreValve. For future work, it would be more beneficial to 
determine the mortality and stroke rates with a larger patient population and compare the different demographics 
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